RESEARCH

LAPD focuses on the development of next-generation delivery systems for RNA-based therapeutics, including ASO, siRNA, and IVT mRNA.
Our research centers on designing and optimizing cationic lipid formulations, lipid nanoparticles (LNPs), and other novel delivery platforms that enhance stability, targeting specificity, and intracellular delivery efficiency.

We also explore ligand–RNA conjugate strategies to achieve tissue- or cell-selective delivery, integrating principles from pharmaceutics, biomaterials engineering, and pharmacokinetics.
Through these efforts, LAPD aims to establish safe, effective, and clinically translatable delivery solutions that advance the field of gene therapy.

This research area focuses on the design of peptide-based prodrug systems that integrate self-assembly with disease-responsive activation.
These therapeutic platforms are engineered to self-organize into nanoscale structures, selectively activate in pathological tissues, and enhance therapeutic efficacy while minimizing systemic side effects.

Computational approaches, including molecular docking and molecular dynamics simulations, are employed as rational design tools to predict molecular interactions and optimize activation profiles.

LAPD develops inorganic and hybrid nanomaterials designed to modulate reactive oxygen species (ROS) levels and alleviate inflammation-induced tissue damage.

These multifunctional nanotherapeutics show broad potential across inflammatory and degenerative diseases, and ongoing research explores their integration with RNA delivery systems to achieve disease-modifying therapeutic outcomes. 

We are developing multifunctional nanoplatforms that integrate drug delivery, diagnostic imaging, and stimuli-responsive mechanisms for precision cancer therapy.
Our work aims to achieve tumor-specific targeting, deep tissue penetration, and real-time therapeutic monitoring, contributing to the advancement of theranostic nanomedicine.

Our lab conducts pharmaceutics-based formulation research, focusing on formulation design, controlled release, and stability evaluation.

We aim to bridge nanomedicine research with practical pharmaceutical development, ensuring scalability and regulatory alignment for clinical translation. 

LAPD is actively engaged in research that bridges gene therapy development and regulatory science.
Our goal is to establish safe, efficient, and clinically translatable gene therapy platforms, while contributing to the scientific foundation for regulatory evaluation of advanced biotherapeutics.

Through the integration of pharmaceutics, nanomedicine, and regulatory science, we seek to define quality, safety, and efficacy standards that support the bench-to-bedside translation of RNA and gene therapeutics.
This effort aligns with the national and institutional initiatives promoting science-driven regulatory innovation for next-generation therapies.